New data support antitumour drug misetionamide in ovarian cancers
New published data have demonstrated positive monotherapy results for misetionamide as well as synergistic activity with PARP inhibitors (PARPis) and bevacizumab antineoplastic in ovarian cancer.
Misetionamide is a tumour cell selective small molecule drug that is broadly active in multiple cancer models.
Misetionamide’s inhibition of hexokinase-2 (HK-2), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and pyruvate dehydrogenase (PVD) in aerobic glycolysis inhibits ATP production for cancer cells, setting up oxidative, metabolic and hypoxic stresses within the cancer cell.
Additionally, misetionamide’s inhibition of key transcription factors such as NFkB further impairs the ability of the cancer cell to express genes and thus sustain viability and proliferation.
“The key findings in our research are that misetionamide exerts a profound antitumour effect when used as monotherapy as well as synergistically when used either in combination with PARP inhibitors or bevacizumab. Misetionamide also has anti-angiogenic activity that interacts synergistically with bevacizumab. Both findings, and others, strongly suggest that misetionamide in combination with PARPi or bevacizumab should be studied further as a new antitumour drug in ovarian cancers,” said Dr Anil Sood, Department of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center.
Developer Panavance Therapeutics has announced plans to initiate two clinical studies: a Phase I/II study of misetionamide for the treatment of platinum-resistant ovarian cancer and a clinical trial as a first-line maintenance therapy for non-BRCA mutated pancreatic cancer patients.
Preclinical studies have demonstrated that misetionamide’s broadly anti-neoplastic MOA has the potential to be effective in additional tumour types, including melanoma, squamous cell, breast, and colorectal cancers.
“This research demonstrates that misetionamide exerts major anti-cancer effects through new metabolic and transcription inhibition mechanisms. As such, misetionamide may be a promising new therapeutic approach for ovarian cancer patients, which is the fifth leading cause of female cancer death,” commented study author, Robert Coleman, Gynecologic Oncologist, Texas Oncology.
Diana Spencer, Senior Digital Content Editor, DDW
